http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
제3차 전력수급기본계획에서의 적정 양수발전기 규모 검토
박만근(Park Marn Geun),양성배(Yang Sung Bae),유헌수(Ryu Heon Su) 대한전기학회 2007 대한전기학회 학술대회 논문집 Vol.2007 No.11
구조개편 이후 전력수급계획 수립여건이 한 전의 독점적 계획에서 사업자 건설의향으로 전환됨에 따라 신규설비 건설계획은 수익성 위주로 전환되었다. 이에 따라 본 논문에서는 기저설비(원자력, 석탄화력) 운전효율성 향상 차원에서 건설되던 양수설비의 적정 설비규모를 계통 공급신뢰도 측연, 에너지 이용 효율성 향상 측연, 전력시장 에서의 경제성 측면에서 검토하여 최적전원구성(Best Fuel Mix) 유도를 위한 정책적 방향을 제시하였다.
P-Pool 모형을 활용한 장기 전력시장가격(SMP) 전망
김은환(Kim Eun Hwan),양성배(Yang Sung Bae),박만근(Park Marn Geun),조춘택(Cho Chun Taek) 대한전기학회 2007 대한전기학회 학술대회 논문집 Vol.2007 No.11
전력산업 구조개편에 따라 도입된 새로운 전력시장환경하에서 전력시장가격(SMP)은 시장참여자에게 있어 기존사업 운영 및 신규투자에서의 의사결정을 하는데 가장 중요한 요소로 작용하게 된다. 이에, 본 논문에서는 전력시장 시뮬레이션 모형인 P-Pool 모형을 활용하여 제3차 전력수급기본계획에 기준한 장기 전력시장가격(2007-2020)을 전망하고 이를 시장정보로 제공함으로써 향후 잠재적 시장참여자의 의사결정을 돕고자 한다.
성인 국소성 분절성 사구체 경화증의 임상경과 및 치료반응
홍화정(Hwa Jeong Hong),임천규(Chun Gyoo Ihm),최태진(Tae Jin Choi),이성배(Sung Bae Lee),최남수(Nam Soo Choi),홍성표(Sung Pyo Hong),이태원(Tae Won Lee),김명재(Myung Jae Kim),양문호(Mun Ho Yang) 대한내과학회 1998 대한내과학회지 Vol.54 No.2
Background: The response to therapy in adult patients with nephrotic syndrome caused by primary focal segmental glomerulosclerosis (FSGS) was discouraging, but recent reports have shown high remission rate. Of these patients in remission, few progressed to end stage renal disease. Methods : we analyzed author's experiences in 42 Korean adults with primary FSGS between January 1986 and December 1995 in attempt to know the response to therapy and outcome. Results: 1) Twenty-six of 42 patients(62%) had nephrotir range proteinuria, and renal insufficiency (serum creatinine>1.4 mg/dL ) was present in 14 patients(34%). Nephrotic patients had higher serum level of creatinine than that of nonnephrotic patients, and there was no difference between the two groups in blood pressure, age, and hematuria. 2) Twenty-six patients with nephrotic range proteinuria received combined treatment with prednisolone and cyclophosphamide. Complete remission (proteinuria≤300 mg/d) was observed in 10 cases(39%), and partial remission(≤2.50g/d) in 10 cases(42%), with mean remission time of 4.1±2.2 months after initiation of treatment. They had remission within 6 months of therapy except one. Relapse was noticed in 11 cases (52%) during follow-up. 3) None of responder group progressed to ESRD, while two of 5 non-responders progressed to ESBD, but there was no significant difference in slope of inverse creatinine between two groups. 4) The degree of proteinuria, initial serum creatinine, age, and sex did not affect the patient's response to therapy 5) The risk factors related to progression of renal failure were the initial serum creatinine level and degree of proteinuria. Conclusion: Nephrotic adult patients with primary FSGS may benefit from a more prolonged course of therapy with prednisolone and cyclophosphamide.
아칼라지아 환자에서 내시경적 하부식도 괄약근내 보툴리늄독소 주사의 효과
김병호,이정일,김효종,이성배,장린,동석호,장영운,양형인,김덕윤 대한소화기내시경학회 1998 Clinical Endoscopy Vol.18 No.3
Background/Aims: Botulinum toxin(Botox) has long been known as one of the most potent paralytic agents of skeletal muscle, and acts by inhibiting the acetylcholine release from nerve terminals. Recently lacally injected Botox has been found to be effective in the reduction of lower esophageal sphincter(LES) tone in patients with achalasia. The aim of this study was to examine the effects of Botox on patients with achalasia in terms of symptomatic relief and improvement of esophageal function. Methods: Nine patients with achalasia were given endoscopic injections of 100 units of Botox into the LES. One week later, the response to treatment was assessed on the basis of changes in the symptomatic scores, maximal diameters of esophagus clilation on esophagograms, and results of esophageal manometric and scintigraphic studies. Three months later, the symptomatic scores and esophageal manometric results were assessed. Responders to Botox were defined as patients with a decrease in the total symptom score of 50% or more at 1 month of past-treatment without a subsequent treatment. Results: All of the 9 patients improved initially, but only 7 patients had sustained improvement beyond 3 months. One week after treatment, the mean decrease in the symptomatic score was 4.6 points(from 6.7 to 2.7 p$lt;0.05). The mean decrease in the resting LES pressure was 15.5 mmHg(from 42.4 to 26.9 p$lt;0.05) and the mean increase in swallow-induced LES relaxation was 34.4%(from 36.9 to 71.3, p$lt;0.05). The mean decrease in 5-minute retention of 99 m-Tc sulfur colloid was 33%(from 39.6 to 6.6 p$lt;0.05). And the mean decrease in esophageal diameter was 1.3cm(from 4.3 to 3.0 p$lt;0.05). Three months later, the seven responders were still in remission in symptom scores and manometirc findings. One of these 7 responders reported relapsing to the previous symptoms 6 months later. Conclusions: Botulinum toxin is an effective, simple, and safe treatment for achalasia in 78%(7/9) of patients, with a duration of response averaging 9 months. Lon-term studies on the use of Botox need to be conducted.